Martin Zweig Detailed Fundamental Analysis

Validea's guru fundamental report rates UnitedHealth Group (UNH) at 77% using its Martin Zweig Growth Investor model, a strategy targeting growth stocks with accelerating earnings and sales, reasonable valuations, and low debt. Despite the Zweig strategy's proven track record of 15.9% annual returns, UNH's score falls below the 80% threshold for 'some interest,' primarily due to inconsistencies in revenue-to-EPS growth and recent earnings growth rates, even as it passes on P/E and current quarter earnings.

Analysis

UnitedHealth Group (UNH) scores a 77% on Validea's Growth Investor model, a framework based on the Martin Zweig strategy, placing it just below the 80% threshold that signals model interest. The analysis reveals a fundamentally sound company with a qualified growth profile. UNH exhibits strength in several areas, passing tests for its P/E ratio, sales growth rate, earnings persistence, and long-term EPS growth. Notably, its current quarter earnings are strong, showing positive growth year-over-year and exceeding the performance of the prior three quarters. However, the score is held back by critical failures for a growth-focused methodology. The company fails on the metric comparing revenue growth to EPS growth, and it does not show a consistent earnings growth rate over the past several quarters. Furthermore, the current quarter's strong EPS growth did not surpass the company's historical growth rate, indicating a lack of the sustained acceleration that the Zweig model specifically prioritizes.

Key Decisions for Investors

• Investors should view UNH as a company with solid fundamentals but recognize its 77% score reflects a lack of the consistent earnings acceleration that pure growth strategies typically require.
• Given the failure in the relationship between revenue and EPS growth, it is prudent to scrutinize future earnings reports for margin trends and the drivers behind bottom-line performance.
• The mixed signals suggest that while long-term holders may find justification to maintain positions based on valuation and persistence, new investors with a growth mandate should seek evidence of re-accelerating earnings before committing capital.